Published in AIDS Weekly, October 7th, 2002
Gail Skowron and colleagues at Roger Williams Medical Center in Providence, Rhode Island, the University of Colorado in Denver, the AIDS Research Consortium of Atlanta, the University of Alabama in Birmingham, GlaxoSmithKline in Research Triangle Park, North Carolina, Bristol-Myers Squibb in Plainsboro, New Jersey, and Gilead Sciences in Foster City, California assessed the benefits of once-daily treatment with adefovir dipivoxil, lamivudine, didanosine, and efavirenz.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.